HIV

Applying novel and effective approaches based on behavioral economics for pre-exposure prophylaxis (PrEP) dissemination programs could help to tailor the programs to the populations and settings of areas with high HIV burden.

An intervention for Black women living with HIV was shown to have improved perceived outcomes when incorporating a support network and when the program structure emphasized trust.

Women living with HIV reported their experiences living with the disease, highlighting discrimination in their social lives.

Patients with HIV were able to maintain care and achieve viral suppression with differentiated service delivery models with comparable effectiveness to the standard of care.

Access to HIV testing and pre-exposure prophylaxis could benefit from being tailored to the type of exchange sex.

Interventions should be tailored to local factors when aiming to reduce the risk of HIV in rural residents who use drugs.

The US Preventive Services Task Force (USPSTF) has recommended that clinicians prescribe pre-exposure prophylaxis (PrEP) to decrease the risk of acquiring HIV.

Men who have sex with men living with HIV were found to have diagnosis rates of sexually transmitted infections (STIs) that were stable throughout the COVID-19 pandemic.

The overall burden of aging-related comorbidities was higher in women compared with men, especially in people living with HIV.

A global assessment found that there was a high prevalence of chronic pain in women living with HIV.

Female sex workers were found to have tested for HIV less in 2020 than had been reported in 2015.

New research found that women in Somalia relied on television and radio to learn about HIV/AIDS.

The results found within women living with HIV and women without HIV differed from those found in a similar study on men living with HIV and men without HIV.

Evidence shows almost zero risk of sexual transmission when HIV viral loads are less than 1000 copies/mL, which could allow providers to destigmatize HIV and promote antiretroviral therapy adherence.

Women with HIV who reported heavy alcohol use were more likely to have lower self-reported health status, but this association was not seen in men with HIV.

Comorbidities assessed included cardiovascular, cancer, pulmonary, and mental health diagnoses, chosen due to their relation to smoking and their substantial mortality burden.

Researchers found that Beijing residents with HIV sought out treatment earlier after China updated its HIV treatment guidelines in 2016.

Researchers summarized the limited available data on human papillomavirus (HPV) vaccine efficiency and immunogenicity in people living with HIV and gave insight into topics for further research.

Aging people with HIV need more assistance from various industry leaders that go beyond just raising awareness.

New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.

A new study has found that initial visits and the number of viral load tests decreased during the COVID-19 pandemic but viral suppression and hospitalizations remained stable.

Interpersonal support, residing in a rural area, and not disclosing HIV status to partners were all found to be linked to higher antiretroviral therapy (ART) adherence, all at different degrees.

A new model produces information that can lead to individual providers identifying women who may need more targeted and more frequent HIV testing or be good candidates for preexposure prophylaxis.

Preliminary data suggest the number of meningococcal disease cases among individuals with HIV doubled in 2022, while vaccination rates for the disease remain low.

An evaluation of a same-day HIV pre-exposure prophylaxis (PrEP) program in Jackson, Mississippi, showed that most individuals given a same-day prescription either never started PrEP or stopped use within 3 months.

Among women on Medicaid, the prevalence of Kaposi sarcoma—a cancer commonly associated with HIV—was 82 times higher in women with HIV compared with women without HIV.

According to new estimates, the US government spent between $143 million and $314 million in 2022 inflation-adjusted dollars funding the development of tenofovir disoproxil fumarate-emtricitabine. The previous estimate was around $50 million.

A CDC report emphasized the need for increased investments, innovation, and focus on equity in order to end the HIV epidemic.

Between 2010 and 2020, pediatric antiretroviral therapy (ART) coverage tripled, but still consistently lagged behind adult ART coverage.

Jessica Robinson-Papp, MD, MS, professor of neurology at Icahn School of Medicine at Mount Sinai, talks about how autonomic neuropathy in people with HIV needs more study.